- The company is expanding its presence in the global surgical robotics market through its proprietary SSi Mantra robotic surgery platform.
- The company’s strategy combines world-class robotic systems, including telesurgery capabilities, with affordability, physician training, and international market expansion.
- More than 200 SSi Mantra systems have been installed worldwide, supporting over 12,000 robotic procedures across more than 170 surgical indications.
- SS Innovations continues pursuing U.S. FDA clearance and European regulatory approvals while building its installed base internationally.
- Growing demand for minimally invasive surgery and broader access to robotic procedures continues to create opportunities for emerging high-tech medical technology companies.
The market for robotic-assisted surgery continues to evolve as healthcare systems seek technologies that can improve surgical precision while expanding patient access. Within that landscape, SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has positioned itself around a strategy centered on unmatched technology, physician training, international expansion, and affordability. Serving as the foundation of its commercial efforts is the company’s proprietary SSi Mantra surgical robotic system.
Unlike many developers focused primarily on premium hospital systems, SS Innovations has concentrated on reducing the economic barriers that have limited adoption of robotic surgery in many regions. The company believes lowering acquisition and operating costs can allow more hospitals to introduce robotic-assisted procedures without sacrificing advanced functionality.
That strategy has translated into continued operational growth. According to the company, more than 200 SSi Mantra systems have now been installed globally, supporting more than 12,000 multi-specialty robotic procedures, including cardiac surgery, pediatric procedures and robotic telesurgery. The platform has also been used across more than 170 different surgical procedures, illustrating its applicability across multiple clinical specialties.
Cardiac surgery remains an area of particular differentiation. While several robotic platforms are designed primarily for soft-tissue procedures, SS Innovations has invested heavily in robotic cardiac surgery, one of the most technically demanding surgical disciplines. The company reports that the SSi Mantra has supported more than 650 cardiac procedures, providing surgeons with robotic capabilities for complex minimally invasive operations.
The platform incorporates three to five modular robotic arms, an open-console surgeon workstation, high-definition 3D visualization and a portfolio of more than 40 robotic surgical instruments. The company has also developed complementary SSi Mudra instruments that support a broad range of minimally invasive procedures.
Beyond the operating room, SS Innovations has devoted considerable resources to telesurgery. Although remote robotic surgery remains an emerging field and is not currently the company’s primary commercial business, it represents an area receiving increasing attention across healthcare. The SSi Mantra platform has now been used in more than 170 telesurgery procedures, including more than 20 cardiac telesurgeries, which the company says makes it the only robotic surgical platform to have performed cardiac telesurgery.
Management views telesurgery as part of a broader effort to extend specialist surgical expertise into communities where experienced robotic surgeons may not be physically available. Related teleproctoring technologies also allow experienced physicians to mentor surgeons remotely during procedures.
Equally important to the company’s long-term strategy is physician education. Earlier this month, SS Innovations graduated the inaugural class of its SS International Centre for Robotics Surgery (“SSICRS”) cardiac robotic surgery training program. The five-day course brought together 33 healthcare professionals from seven countries for classroom instruction, laboratory sessions, live surgical demonstrations and hands-on robotic training.
The company intends to expand the educational program beyond cardiac surgery into additional specialties including urology, gynecology, thoracic surgery, gastrointestinal procedures, colorectal surgery and general surgery.
Corporate leadership continues to evolve alongside commercial expansion. SS Innovations recently announced the appointment of veteran medical technology executive Sarah M. Romano as Chief Financial Officer, effective August 3. Romano brings more than two decades of public-company finance and capital markets experience, including leadership positions with emerging medical technology companies. According to the company, she has helped raise more than $100 million during her career.
Management believes the appointment strengthens financial leadership as SS Innovations expands internationally while continuing preparations for U.S. regulatory review.
Regulatory progress remains another important focus. The company continues pursuing U.S. Food and Drug Administration (“FDA”) clearance for the SSi Mantra platform while also advancing European certification activities. Entry into additional regulated markets could significantly expand the company’s commercial opportunities over time, although regulatory review remains an ongoing process.
Artificial intelligence also forms part of SS Innovations’ longer-term development roadmap. According to CEO and founder Dr. Sudhir Srivastava, AI already contributes to certain safety functions within the robotic platform, while future development may incorporate additional imaging capabilities, workflow automation and greater surgical assistance. The company is also evaluating specialty-specific robotic platforms, pediatric applications, mobile operating units and robotics designed for military and disaster-response environments.
The broader market backdrop continues to support interest in robotic surgery. Hospitals increasingly seek minimally invasive techniques that may shorten recovery times and improve procedural precision. The unmatched technology behind the SSi Mantra robotic surgery platform meets this need, while also offering affordability for healthcare providers balancing clinical benefits against capital costs.
For more information, visit the company’s website at www.SSInnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com
MissionIR is powered by IBN